Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453061 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNH2CHRNA7 | |
| SCHEMBL14410831 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNH2CHRNA7 | |
| SCHEMBL911696 | 0.93 | SLC6A4 (0.88) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL910969 | 0.93 | SLC6A4 (0.88) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL910970 | 0.93 | SLC6A4 (0.88) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL911647 | 0.81 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL911664 | 0.81 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL911648 | 0.81 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL1029509 | 0.81 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL1029510 | 0.81 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | SLC6A4 1446/4885SLC6A2 1034/4885SLC6A3 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.